UNSPSC 51171938: Enprostil

This classification denotes an anti-ulcer agents and prostaglandins e, synthetic, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier J4IP5Z9DAU. European Medicines Agency schedules Enprostil in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB06549MIG. Enprostil generally arises in the molecular formula C23H28O6.

The term ENPROSTIL is an International Non-Proprietary Name or INN (see WHO INN reference publication, Volume 38, no. 6, 1984, list 24.) ENPROSTIL is scheduled in the U.S. International Trade Commission's Harmonized Tariff System (HTS) Pharmaceutical Appendix. Most nations schedule enprostil under HS 29375000 and SITC 54156. As of Q4 2014, ENPROSTIL remains the US FDA Preferred Term for this commodity. SMILES: OC1C(C(C(=O)C1)CC=C=CCCC(=O)OC)/C=C/C(O)COC1CCCCC1.

UNSPSC 51171938 Enprostil is a Commodity code under which state and local governments procure pharmaceutical products, specifically generic multi-source pharmaceuticals and over-the-counter offerings distributed through established wholesaler networks to public health and correctional facilities. Recent solicitations show two distinct procurement streams: direct services contracts for specimen collection and drug testing using pharmaceutical screening methodologies, and supply agreements for bulk pharmaceutical distribution across multistate cooperative purchasing vehicles. The issuing bodies are diverse, spanning state health and human services commissions, county correctional departments, and state procurement offices operating multistate cooperative purchasing alliances. Collin County Community Supervision and Corrections Department (Texas) is actively soliciting offender specimen collection and drug testing services under RFP 2026-327, with proposals due July 23, 2026 at 2:00 p.m., for an estimated contract value of $600,000 over two years with three optional one-year renewals; the scope encompasses staffing two collection sites, operating randomized testing notification systems, immunoassay screening with LC/MS/MS or GC/MS confirmation, and alternative testing methodologies including oral fluid and hair testing, with approximately 25,031 tests annually. The Texas Health and Human Services Commission issued RFI HHS0017013 in March 2026 to gather market intelligence on direct-to-manufacturer prescription programs before launching a formal RFP, signaling future procurement activity in pharmacy benefit management.

Recent activity clusters in Texas and the upper Midwest. The Minnesota Multistate Cooperative Purchasing Alliance (MMCAP), administered by the Minnesota Department of Administration, issued RFP S1070000015802 on January 20, 2026, with a proposal deadline of March 26, 2026, to establish multiple contracts for generic multi-source pharmaceuticals and over-the-counter products for distribution across participating state and local government facilities including Oregon; the RFP requires vendors to supply through three authorized wholesalers (AmerisourceBergen Drug Corporation, Cardinal Health, and Morris & Dickson Co.), maintain current Good Manufacturing Practices and Drug Supply Chain Security Act compliance, hold comprehensive insurance coverage including $5 million commercial general liability per occurrence, and compete on price competitiveness weighted at 75 percent with products effective July 1, 2026. The geographic spread reflects activity in Texas health and human services procurement and multistate cooperative purchasing initiatives spanning the upper Midwest and Pacific Northwest.